ATE243747T1 - Herstellung von antikörpern - Google Patents

Herstellung von antikörpern

Info

Publication number
ATE243747T1
ATE243747T1 AT92306420T AT92306420T ATE243747T1 AT E243747 T1 ATE243747 T1 AT E243747T1 AT 92306420 T AT92306420 T AT 92306420T AT 92306420 T AT92306420 T AT 92306420T AT E243747 T1 ATE243747 T1 AT E243747T1
Authority
AT
Austria
Prior art keywords
antibodies
production
same
recombinant
prophylaxis
Prior art date
Application number
AT92306420T
Other languages
English (en)
Inventor
James Scott Crowe
Alan Peter Lewis
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE243747(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919115284A external-priority patent/GB9115284D0/en
Priority claimed from GB919116594A external-priority patent/GB9116594D0/en
Priority claimed from GB929206284A external-priority patent/GB9206284D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE243747T1 publication Critical patent/ATE243747T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92306420T 1991-07-15 1992-07-14 Herstellung von antikörpern ATE243747T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919115284A GB9115284D0 (en) 1991-07-15 1991-07-15 Production of antibodies
GB919116594A GB9116594D0 (en) 1991-08-01 1991-08-01 Production of antibodies
GB929206284A GB9206284D0 (en) 1992-03-23 1992-03-23 Production of antibodies

Publications (1)

Publication Number Publication Date
ATE243747T1 true ATE243747T1 (de) 2003-07-15

Family

ID=27265765

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92306420T ATE243747T1 (de) 1991-07-15 1992-07-14 Herstellung von antikörpern

Country Status (16)

Country Link
US (1) US5876961A (de)
EP (1) EP0523949B1 (de)
JP (1) JP3502093B2 (de)
KR (1) KR100255717B1 (de)
AT (1) ATE243747T1 (de)
AU (1) AU662752B2 (de)
CA (1) CA2111858A1 (de)
DE (1) DE69233104T2 (de)
ES (1) ES2199216T3 (de)
FI (1) FI940144L (de)
HU (1) HU220355B (de)
IE (1) IE922287A1 (de)
IL (1) IL102490A0 (de)
NZ (1) NZ243558A (de)
TW (1) TW373023B (de)
WO (1) WO1993002190A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
EP0605442B1 (de) * 1991-07-25 2003-04-16 Idec Pharmaceuticals Corporation Rekombinante antikörper zur humanen therapie
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US20020122807A1 (en) * 1998-07-07 2002-09-05 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
ATE414151T1 (de) 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
ES2258558T3 (es) * 2000-12-05 2006-09-01 Alexion Pharmaceuticals, Inc. Anticuerpos diseñados racionalmente.
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
CN105884893A (zh) 2002-07-18 2016-08-24 莫鲁斯有限公司 抗体混合物的重组生产
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2554054C (en) 2004-01-20 2013-06-04 Merus B.V. Mixtures of binding proteins
WO2006014498A2 (en) * 2004-07-06 2006-02-09 Bioren, Inc. Universal antibody libraries
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
ITRM20050297A1 (it) * 2005-06-08 2006-12-09 Univ Siena Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi.
CN103276033A (zh) 2006-09-13 2013-09-04 雅培制药有限公司 细胞培养改良
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2008094316A2 (en) 2006-09-22 2008-08-07 Stowers Institute Of Medical Research Novel branchiostoma derived fluorescent proteins
EP2098536A1 (de) 2008-03-05 2009-09-09 4-Antibody AG Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
ES2667493T3 (es) 2008-11-14 2018-05-11 Viacyte, Inc. Encapsulación de células pancreáticas derivadas de células madre humanas pluripotentes
US9079942B2 (en) 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
US10585098B2 (en) 2009-11-23 2020-03-10 The Johns Hopkins University Optimizing diagnostics for galactofuranose containing antigens
WO2011063395A2 (en) 2009-11-23 2011-05-26 The Johns Hopkins University Lateral flow device for diagnosing microbial infections
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
PL2900694T3 (pl) 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t
EP2830651A4 (de) 2013-03-12 2015-09-02 Abbvie Inc An humanes tnf-alpha bindende humane antikörper und verfahren zur herstellung davon
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
JP6205175B2 (ja) 2013-05-16 2017-10-04 株式会社Ｒｅｓｖｏ 精神・神経疾患バイオマーカー
EP3052640A2 (de) 2013-10-04 2016-08-10 AbbVie Inc. Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10107822B2 (en) 2013-12-16 2018-10-23 The Johns Hopkins University Interferon-gamma release assays for diagnosis of invasive fungal infections
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
RS66392B1 (sr) 2014-02-28 2025-02-28 Merus Nv Antitelo koje vezuje erbb-2 i erbb-3
LT3115376T (lt) 2015-07-10 2018-11-12 Merus N.V. Antikūnai, kurie jungiasi su žmogaus cd3
US11939394B2 (en) 2015-10-23 2024-03-26 Merus N.V. Binding molecules that inhibit cancer growth
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
EP3606964A4 (de) 2017-04-03 2020-12-09 Immunomedics, Inc. Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie
EP3625264B9 (de) 2017-05-17 2023-10-25 Merus N.V. Kombination eines erbb-2 / erbb-3-bispezifischen antikörpers mit endokrin-therapie für brustkrebs
PL3665198T3 (pl) 2017-08-09 2025-06-09 Merus N.V. Przeciwciała wiążące egfr i cmet
EP3693013A4 (de) 2017-10-06 2021-06-30 Ono Pharmaceutical Co., Ltd. Bispezifischer antikörper
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
TW202509079A (zh) 2019-04-04 2025-03-01 日商小野藥品工業股份有限公司 雙特異性抗體
US20220372148A1 (en) 2019-07-05 2022-11-24 Ono Pharmaceutical Co., Ltd. A pharmaceutical composition for treating hematological cancer
CA3149309A1 (en) 2019-07-30 2021-02-04 Ono Pharmaceutical Co., Ltd. Bispecific antibody
WO2021025140A1 (ja) 2019-08-08 2021-02-11 小野薬品工業株式会社 二重特異性タンパク質
KR20250052397A (ko) 2022-08-23 2025-04-18 오노 야꾸힝 고교 가부시키가이샤 이중 특이성 항체

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296024A (en) * 1974-12-09 1981-10-20 Merck & Co., Inc. Human immune serum globulin with high hepatitis A antibody titer
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
JPS6054687A (ja) * 1983-07-19 1985-03-29 スロ−ン−ケツタリング　インステイテユ−ト　フオ−　キヤンサ−　リサ−チ ヒト　モノクロ−ン抗体の製法
US4777245A (en) 1984-01-06 1988-10-11 Genelabs Incorporated Non-human primate monoclonal antibodies and methods
US4997764A (en) * 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
WO1989000607A1 (en) * 1987-07-09 1989-01-26 The United States Of America, As Represented By Th Preparation of human monoclonal antibodies of selected specificity and isotypes
NZ226694A (en) * 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
HU218093B (hu) * 1988-10-19 2000-05-28 Dow Chemical Co. Rák kezelésére alkalmazható, nagy affinitású, módosított antitestek új csoportja, eljárás előállítására, valamint az antitesteket tartalmazó konjugátumok és készítmények
DE3921211C1 (de) * 1989-06-28 1990-11-29 Idt Ag Fuer In Vivo Diagnostik Und Therapie, Zuerich, Ch
WO1991004336A1 (en) * 1989-09-19 1991-04-04 Centocor, Inc. Method for improving human monoclonal antibody production
GB8925590D0 (en) * 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
DE4002897A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
ES2336444T3 (es) * 1990-02-01 2010-04-13 Siemens Healthcare Diagnostics Products Gmbh Obtencion y empleo de ginotecas de anticuerpos humanos ("bancos de anticuerpos humanos").
EP0605442B1 (de) * 1991-07-25 2003-04-16 Idec Pharmaceuticals Corporation Rekombinante antikörper zur humanen therapie

Also Published As

Publication number Publication date
DE69233104D1 (de) 2003-07-31
JPH07502882A (ja) 1995-03-30
JP3502093B2 (ja) 2004-03-02
ES2199216T3 (es) 2004-02-16
FI940144A0 (fi) 1994-01-12
FI940144A7 (fi) 1994-01-12
FI940144L (fi) 1994-01-12
AU662752B2 (en) 1995-09-14
IL102490A0 (en) 1993-01-14
IE922287A1 (en) 1993-01-27
HU9400110D0 (en) 1994-05-30
EP0523949B1 (de) 2003-06-25
HUT69798A (en) 1995-09-28
NZ243558A (en) 1994-06-27
KR100255717B1 (ko) 2000-05-01
AU2279892A (en) 1993-02-23
WO1993002190A1 (en) 1993-02-04
EP0523949A1 (de) 1993-01-20
DE69233104T2 (de) 2004-05-13
US5876961A (en) 1999-03-02
HU220355B (hu) 2001-12-28
TW373023B (en) 1999-11-01
CA2111858A1 (en) 1993-02-04

Similar Documents

Publication Publication Date Title
ATE243747T1 (de) Herstellung von antikörpern
DE69133397D1 (de) Benzoylderivate
DE69033040D1 (de) Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)
DK140996A (da) Fremgangsmåde til fremstilling af 2,3,4,5-tetraflour-6-alkyl-benzoesyreforbindelser
AU2118488A (en) Improvements in or relating to methods of treating damaged skin
ATE116370T1 (de) Extraktionsmittel für poly-d(-)-3- hydroxybuttersäure.
ATE153648T1 (de) Verwendungen von alpha-hydroxyfettsäuren
DE60114865D1 (de) Heterologe herstellung von polyketiden
ATE162079T1 (de) Verwendung von antikörper enthaltenden präparationen zur immunsuppression
DE59308628D1 (de) Verfahren zur Herstellung von Faktor VIII
DE69021724D1 (de) Modifizierte Protease, Verfahren zu deren Herstellung und diese enthaltende kosmetische Zusammensetzungen.
ATE73462T1 (de) Hirudin-variante, deren verwendung und herstellung.
ATE103779T1 (de) Brausekomponente und verfahren zu ihrer herstellung.
ATE130289T1 (de) 1,3-diphenyl-2-propin-1-one.
ATE63684T1 (de) Deodorant.
NL7017514A (en) Purification of proteins
RO89127A (ro) Compozitie erbicida lichida
DE3851306D1 (de) Verfahren zur Herstellung von optisch-aktiven 1,2-Diolen.
ATE164882T1 (de) Verfahren zur herstellung von aktivierten killer- monozyten und verfahren zur überprüfung ihrer tumoriziden aktivität
FI874996A0 (fi) Diamidien käyttö pehmennysaineena pesuainekoostumuksissa
FI901371A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten halogeeni-3,4-dihydro-bentsotiopyranyyliamiinien valmistamiseksi
DK576887A (da) Farmaceutiske midler
PT87563A (pt) Process for the preparation of vinylcephalosporins useful as medicaments
NO961353D0 (no) Resulfurisert austenittisk rustfritt stål med forbedret bearbeidbarhet
DK44184D0 (da) Kosmetik

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties